Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50< 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux (IC50s< 10 nM).

Balixafortide efficiently blocks SDF-1 dependent chemotaxis of MDA MB 231 breast cancer cells (IC50< 20 nM), Namalwa and Jurkat cells (IC50< 10 nM). Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Jurkat (IC50< 400 nM) and Namalwa (IC50< 200 nM) [1].

Balixafortide is optimized for favorable mouse absorption, distribution, metabolism, and excretion (ADME) properties with balanced plasma protein binding, microsomal stability, and greater plasma.

TP2141

C82H113N22F3O23S2

1896.05

POL6326 TFA;Balixafortide TFA

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years